MacBeth, Kyle J.

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 863

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Sallman, D. A., McLemore, A. F., Aldrich, A. L., Komrokji, R. S., McGraw, K. L., Dhawan, A., Geyer, S., Hou, H.-A., Eksioglu, E. A., Sullivan, A., et al. (2020) · Blood

Acute Myeloid Leukemia ResearchCancer Immunotherapy and Biomarkers

Cited by 196

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

Fang, J., Liu, X., Bolanos, L., Barker, B., Rigolino, C., Cortelezzi, A., Oliva, E. N., Cuzzola, M., Grimes, H. L., Fontanillo, C., et al. (2016) · Nature Medicine

Acute Myeloid Leukemia ResearchProtein Degradation and Inhibitors

Cited by 83